

## 2018 Seminar

[www.hudson.org.au](http://www.hudson.org.au)

### Challenges Facing Translational Research across the Yarra, and around the World

**Dr C. Glenn Begley**


**MB, BS, PhD, FRACP, FRCPA, FRCPath, FAHMS  
CEO, BioCurate Pty Ltd**

Dr Begley is the inaugural CEO of BioCurate, a joint initiative of Monash and Melbourne Universities and created to provide commercial focus in the early phases of drug development. He served as Chief Scientific Officer at Akriveia Therapeutics, California (2016-2027) and TetraLogic Pharmaceuticals, Pennsylvania (2012-2016). From 2002-2012, he was Vice-President and Global Head of Hematology/Oncology Research at Amgen, responsible for building, directing and integrating Amgen's 5 research sites.

It was at Amgen he identified and highlighted the issue of research integrity and scientific reproducibility which has subsequently received considerable international attention.

Before Amgen he had over 20 years of clinical experience in medical oncology and hematology. His personal research focused on regulation of hematopoietic cells and translational clinical trials. His early studies first described human G-CSF, and in later clinical studies, first demonstrated that G-CSF-"mobilized" blood stem cells hastened hematopoietic recovery. This finding revolutionized the clinical approach to bone-marrow transplantation.

His honors include being elected as the first Foreign Fellow to the American Society of Clinical Investigation in 2000, to the Association of American Physicians in 2008, to the Research "Hall of Fame" at his alma mater, the Royal Melbourne Hospital in 2014, and to the Australian Academy of Health and Medical Sciences in 2016.



**DATE**

**THURS 26  
APRIL**

**TIME**

**12.00PM – 1.00PM**

**LOCATION**

**TRF BUILDING  
LEVEL 2, SEMINAR  
ROOMS 1 AND 2**